Quick Summary — PCRX scores higher on quality with 8.7/10 vs PRGO's 5.9/10. PCRX trades at $22.25 while PRGO trades at $10.46. Both analyzed daily using SEC EDGAR data across 13 institutional models.
PCRX scores higher with a 8.7/10 quality rating vs PRGO's 5.9/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.
At $22.25, PCRX trades +165.0% below its Bayesian DCF fair value of $58.96, while PRGO at $10.46 trades +72.4% above its estimate of $2.88. PCRX shows a wider gap between price and intrinsic value.
PCRX earns a Quality of Company score of 8.7/10 compared to PRGO's 5.9/10. This moderate difference suggests one company has an edge in fundamental quality, though both may offer investment merit depending on valuation. The QOC score synthesizes 32 signals spanning profitability margins, revenue growth, free cash flow, capital allocation, and leverage.
PCRX carries a SAFE value trap risk (24/100) while PRGO shows LOW risk (32/100). Both companies show manageable value trap risk, suggesting their current valuations are not artificially depressed by fundamental deterioration.
Both PCRX and PRGO operate in Drug Manufacturers - Specialty & Generic, which has 79 stocks tracked by CirclFi. Same-industry comparisons provide the most direct insight into relative valuation since both companies face similar regulatory environments, market dynamics, and competitive pressures. Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN), and ensemble methods (CUCE).
11 hidden models compare PCRX vs PRGO differently — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more. Some may disagree with the 2 you see above.
Bloomberg Terminal: ~$2,000/mo · FactSet: ~$1,000/mo · CirclFi: $0.90/day
See All 13 Models — $0.90/dayWe don’t predict prices. We show you what 13 independent mathematical frameworks say a stock is worth — and let you decide.